Literature DB >> 18203009

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

Morie Gertz1, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, Nelson Leung, Mark Litzow.   

Abstract

The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06 microg/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06 microg/L had a day-100 all-cause mortality rate of 7% (P < 0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06 microg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18203009     DOI: 10.1080/10428190701684518

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  14 in total

1.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Authors:  Sumit Madan; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; David Dingli; S Vincent Rajkumar; William J Hogan; Nelson Leung; Martha Grogan; Morie A Gertz
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

3.  Current treatment of AL amyloidosis.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

Review 4.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

5.  Troponins in cardiac amyloidosis: multipurpose markers.

Authors:  Federico Perfetto; Franco Bergesio; Michele Emdin; Francesco Cappelli
Journal:  Nat Rev Cardiol       Date:  2014-01-28       Impact factor: 32.419

6.  Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.

Authors:  S Parmar; P Kongtim; R Champlin; Y Dinh; Y Elgharably; M Wang; Q Bashir; J J Shah; N Shah; U Popat; S A Giralt; R Z Orlowski; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

Review 7.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 8.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

9.  Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.

Authors:  Shaji K Kumar; Morie A Gertz; Martha Q Lacy; David Dingli; Suzanne R Hayman; Francis K Buadi; Kristen Short-Detweiler; Steven R Zeldenrust; Nelson Leung; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

10.  Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Authors:  Abdullah S Al Saleh; M Hasib Sidiqi; Eli Muchtar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Rahma M Warsame; Wilson I Gonsalves; Taxiarchis V Kourelis; William J Hogan; Suzanne R Hayman; Prashant Kapoor; Shaji K Kumar; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.